Showing 4881-4890 of 23241 results for "".
The Durability Dilemma
https://reachmd.com/specialty/general-ophthalmology/The-Durability-Dilemma-2510/33129/Hear about new biomarkers for assessing retinal disease activity and their clinical significance when using of second-generation agents.Fluid Foundations: How Location Impacts Outcomes in nAMD
https://reachmd.com/programs/cme/Fluid-Foundations-How-Location-Impacts-Outcomes-in-nAMD-2510/33126/Hear about new biomarkers for assessing retinal disease activity and their clinical significance when using of second-generation agents.Biomarking the Difference: How Second-Generation Therapies are Changing the Game
https://reachmd.com/programs/cme/Biomarking-the-Difference-How-Second-Generation-Therapies-are-Changing-the-Game-2510/32736/Hear about new biomarkers for assessing retinal disease activity and their clinical significance when using of second-generation agents.Early Fluid Resolution – A Key to Long-Term Success
https://reachmd.com/specialty/general-ophthalmology/Early-Fluid-Resolution-A-Key-to-Long-Term-Success-2510/33128/Hear about new biomarkers for assessing retinal disease activity and their clinical significance when using of second-generation agents.Second-Generation Biomarkers for Treatment Outcomes
https://reachmd.com/programs/cme/Second-Generation-Biomarkers-for-Treatment-Outcomes-2510/33097/Hear about new biomarkers for assessing retinal disease activity and their clinical significance when using of second-generation agents.Understanding Dual Inhibition of IL-17
https://reachmd.com/programs/medical-industry-feature/understanding-dual-inhibition-of-il-17/32263/IL-17A and IL-17F play significant roles in rheumatic and psoriatic diseases as they trigger downstream pro-inflammatory responses.1,2 Targeting both IL-17A + IL-17F in vitro provides more inhibition of inflammation vs targeting IL-17A alone.*3-5 BIMZELX (bimekizumab-bkzx) is the only approved theraOh, the Hats You'll Wear! The Many Modalities of Pediatric Obesity Management
https://reachmd.com/programs/cme/oh-the-hats-youll-wear-the-many-modalities-of-pediatric-obesity-management/39966/On-demand webcast of expert faculty presentation on the diagnosis and management of obesity for pediatric patients, including communication and patient-centered care strategies to improve health outcomes.Breast Basics 101: What Every Woman Should Know About Breast Cancer Risk, Screening, & Detection
https://reachmd.com/programs/everyday-family-medicine/breast-basics-101-what-every-woman-should-know-break-cancer-risk-screening-detection/7985/Dr. Monique Gary provides key strategies to helping women better understand breast cancer screening recommendations.Harnessing the Immune Power: A Uniquely Designed PD-1 Inhibitor for Esophageal Cancer
https://reachmd.com/programs/project-oncology/harnessing-the-immune-power-a-uniquely-designed-pd-1-inhibitor-for-esophageal-cancer/35512/Esophageal cancer is the tenth most common cancer worldwide and the sixth most prevalent cause of death due to cancer, which is why having additional treatment options for this disease is crucial.1 One available option, tislelizumab plus platinum-based chemotherapy, was recently approved by the FDAOn the Frontline: Empowering IO Therapies for Patients with HER2-Negative G/GEJC
https://reachmd.com/programs/project-oncology/io-therapies-for-patients-with-her2-negative-ggejc/35513/For patients who are diagnosed with metastatic gastric cancer, the five-year overall survival rate is roughly seven percent, underscoring the need for additional treatment options.1 Fortunately, there has been advancement in gastric cancer care, including the FDA approval of tislelizumab plus platin